ConductScience.org, home

Comparison · NCT01019369-2c8e8408

Self Administration of DMPA vs Clinic Administration of DMPA: Number of Participants Continuing DMPA

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Self Administration of DMPA vs Clinic Administration of DMPA: Number of Participants Continuing DMPA. Trial comparisons, record NCT01019369-2c8e8408. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01019369-2c8e8408

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.8030.70.877wilson
Risk in group 20.7440.5890.854wilson
Risk difference, group 1 minus group 20.059-0.09220.23newcombe hybrid score
Risk ratio, group 1 over group 21.080.871.34log
Odds ratio, group 1 over group 21.40.5623.5log
Number needed to treat, for one more participant with the outcome on Self Administration of DMPA than on Clinic Administration of DMPA16.9from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Self Administration of DMPASelf administration of subcutaneous depot medroxyprogesterone acetate~Medroxyprogesterone 17-Acetate: Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year6176OG000
Group 2Clinic Administration of DMPAClinic administration (routine care) of DMPA~Medroxyprogesterone 17-Acetate: Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year2939OG001

Outcome

Type
SECONDARY
Title
Number of Participants Continuing DMPA
Description
The study was designed to examine the increasing accessibility to DMPA by decreasing the need for multiple clinic visits will increase method continuation rates at all other endpoints.
Time frame
3, 9, 12 months
Population
115 women w 12 month follow-up data (76 and 39) . 10 participants LTFU in self-administration group, and 7 participants LTFU in the clinic administration group.

Source ClinicalTrials.gov

Trial

Title
Study of Self or Clinic Administration of DepoProvera
NCT number
NCT01019369
Phases
NA
Conditions
Contraception
Interventions
Medroxyprogesterone 17-Acetate, Medroxyprogesterone 17-Acetate
Lead sponsor
Carolyn L. Westhoff
Results first posted
2015-04-15

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01019369-2c8e8408